17. Analysis of drug use characteristics of SGLT2 receptor inhibitors in very elderly patients treated as outpatients at Hanoi Heart Hospital
Main Article Content
Abstract
To evaluate the drug use characteristics of SGLT2 receptor inhibitors in very elderly outpatients. Analytical observational, retrospective study of 309 patients aged 85 and over, outpatients from May 2023 to October 2024, at the outpatient department - Hanoi Heart Hospital; the mean age was 88.05 ± 3.09 years (range: 85 - 99), with females accounting for 57.6% of the study population. Initial prescriptions included: Empagliflozin 12.5mg + 10mg (45.7%), Dapagliflozin 10mg (37.2%), Dapagliflozin 5mg (13.6%), Empagliflozin 25mg (1.9%), and Empagliflozin 5mg (1.6%). The mean weight reduction after treatment was 4.39 ± 3.86kg. The average duration of SGLT2i use was 7.77 ± 4.39 months. The overall discontinuation rate was 35.6%; 11.7% of discontinuations indicated a drug-related cause, with causes including urinary tract infections (25%), acute kidney injury (30.6%), hypotension (8.3%), weight loss (2.8%), pneumonia (2.7%), and cardiovascular death (30.6%). Adverse events not requiring discontinuation occurred in 13.9% of patients, including: acute kidney injury (30.2%), weight loss (27.9%), urinary tract infection (13.9%). Thus, although there is a rate of having to stop taking the drug, SGLT2i use was prolonged in very elderly patients.
Article Details
Keywords
Very elderly patients, sodium-glucose cotransporter 2 inhibitors, safety
References
2. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015; 373(22): 2117-2128. doi:10.1056/NEJMoa1504720.
3. Neal B, Perkovic V, Matthews DR, et al. Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial. Diabetes Obes Metab. 2017; 19(3): 387-393. doi:10.1111/dom.12829.
4. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 2019; 380(4): 347-357. doi:10.1056/NEJMoa1812389.
5. Voros G, Ector J, Garweg C, et al. Increased Cardiac Uptake of Ketone Bodies and Free Fatty Acids in Human Heart Failure and Hypertrophic Left Ventricular Remodeling. Circ Heart Fail. 2018; 11(12): e004953. doi:10.1161/CIRCHEARTFAILURE.118.004953.
6. Goldman A, Fishman B, Twig G, et al. The real-world safety profile of sodium-glucose co-transporter-2 inhibitors among older adults (≥ 75 years): a retrospective, pharmacovigilance study. Cardiovasc Diabetol. 2023; 22(1): 16. doi:10.1186/s12933-023-01743-5.
7. Fralick M, Colacci M, Thiruchelvam D, Gomes T, Redelmeier DA. Sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors and the risk of heart failure: A nationwide cohort study of older adults with diabetes mellitus. Diabetes Obes Metab. 2021; 23(4): 950-960. doi:10.1111/dom.14300.
8. Orimo H, Ito H, Suzuki T, Araki A, Hosoi T, Sawabe M. Reviewing the definition of “elderly.” Geriatrics & Gerontology International. 2006; 6(3): 149-158. doi:10.1111/j.1447-0594.2006.00341.x.
9. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016; 37(27): 2129-2200. doi:10.1093/eurheartj/ehw128.
10. American Diabetes Association. Standards of Medical Care in Diabetes-2010. Diabetes Care. 2010; 33(Supplement_1): S11-S61. doi:10.2337/dc10-S011.
11.Chawla LS, Bellomo R, Bihorac A, et al. Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup. Nat Rev Nephrol. 2017; 13(4): 241-257. doi:10.1038/nrneph.2017.2.
12. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004 Jan 10; 363(9403): 157-63. doi: 10.1016/S0140-6736(03)15268-3. Erratum in: Lancet. 2004 Mar 13;363(9412):902. PMID: 14726171.
13. Lunati ME, Cimino V, Gandolfi A, et al. SGLT2-inhibitors are effective and safe in the elderly: The SOLD study. Pharmacol Res. 2022; 183: 106396. doi:10.1016/j.phrs.2022.106396.
14. Ramón Baeza-Trinidad JDML. Safety of SGLT2 inhibitors in very elderly diabetic type 2 patients in real life. Safety of SGLT2 inhibitors in very elderly diabetic type 2 patients in real life. 2023; 5(3): 118-122. doi:10.53986/ibjm.2023.0023.
15. Đinh Thị Lan Anh, Lê Minh Hồng, Nguyễn Thị Thuỳ Linh và cs. Phân tích đặc điểm sử dụng nhóm thuốc ức chế sglt-2 trên người bệnh suy tim nội trú tại viện tim mạch - bệnh viện trung ương quân đội 108. VMJ. 2023; 526(1B). doi:10.51298/vmj.v526i1B.5481.
16. Cheong AJY, Teo YN, Teo YH, et al. SGLT inhibitors on weight and body mass: A meta-analysis of 116 randomized-controlled trials. Obesity (Silver Spring). 2022; 30(1): 117-128. doi:10.1002/oby.23331.
17. Meraz-Muñoz AY, Weinstein J, Wald R. eGFR Decline after SGLT2 Inhibitor Initiation: The Tortoise and the Hare Reimagined. Kidney360. 2021; 2(6): 1042-1047. doi:10.34067/KID.0001172021.
18. Rigato M, Fadini GP, Avogaro A. Safety of sodium-glucose cotransporter 2 inhibitors in elderly patients with type 2 diabetes: A meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2023; 25(10): 2963-2969. doi:10.1111/dom.15193.
19. Tumminia A, Graziano M, Vinciguerra F, Lomonaco A, Frittita L. Efficacy, renal safety and tolerability of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in elderly patients with type 2 diabetes: A real-world experience. Prim Care Diabetes. 2021; 15(2): 283-288. doi:10.1016/j.pcd.2020.10.002.